Atlas Trials

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Clinical trial NCT05193448 · COMPLETED

Trial details

NCT number
NCT05193448
Sponsor
French Innovative Leukemia Organisation
Status
COMPLETED
Study type
OBSERVATIONAL
Refractory AMLRelapsed Adult AMLFLT3-TKD MutationFLT3-ITD
Start date
2021-07-05
Primary completion
2021-10-31
Enrollment
177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.